Mestinon (Pyridostigmine Bromide)

Pyridostigmine blocks the enzyme acetylcholinesterase, which normally breaks down acetylcholine. By inhibiting this enzyme, the drug raises acetylcholine levels at neuromuscular junctions, enhancing nerve‑to‑muscle signaling and improving muscle contraction.

The appropriate dose of Mestinon is individualized by the prescribing clinician based on the patient’s specific condition, severity, renal function, and response to therapy. No fixed regimen is provided here; the prescriber sets the dosage.

Safety data for pyridostigmine in pregnancy and lactation are limited. Use is generally reserved for situations where the potential benefit outweighs any possible risk, and the decision should be made by a qualified healthcare professional.

To request Mestinon, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mestinon is a reversible, peripherally acting acetylcholinesterase inhibitor with a relatively short half‑life, making it suitable for chronic conditions like myasthenia gravis. Compared with agents such as neostigmine, it has a slower onset but longer duration, and it is less likely to cross the blood‑brain barrier, reducing central side effects.

Mestinon should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight to maintain stability and potency.

Mestinon is taken orally, usually with a glass of water. It may be administered with or without food, but consistent timing relative to meals helps maintain stable drug levels. The exact schedule is determined by the prescribing clinician.

The most critical risks include cholinergic crisis, which presents as severe muscle weakness and respiratory compromise, marked bradycardia, bronchospasm, and rare but life‑threatening allergic reactions such as anaphylaxis. Patients should be monitored for these signs, especially when doses are escalated.

Mestinon is contraindicated in patients with known hypersensitivity to pyridostigmine or any component of the formulation, and it should be used with caution in individuals with severe asthma, uncontrolled cardiac arrhythmias, or significant renal impairment without appropriate dose adjustment.